About VITRAC Therapeutics, LLC:

VITRAC is an integrated oncology research and development company with experience in developing, managing, and optimizing global pharmaceutical drug development programs from late discovery, translational research, and clinical development through market authorization and post-marketing life-cycle management.

About Oral Aurora A Kinase (AURKA) Specific Inhibitor, VIC-1911:

VIC-1911 is a novel, selective, and orally active inhibitor of Aurora A kinase, a key regulator in mitotic cell division.  Aurora A is associated with the spindle assembly checkpoint and the regulation of the transition from G2 to M phase, and its overexpression associated with poor disease progression and survival in a wide variety of cancers. Therefore VIC-1911 could be a fundamental and transformative anticancer drug. Two Phase-1 clinical studies were conducted to assess safety and tolerability, and to determine the maximum-tolerated dose (MTD), recommended phase 2 dose (RP2D), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of VIC-1911. Now the global development of VIC-1911 has begun with new translational and regulatory strategies.